Seroprevalence of Pertussis in Senegal: A Prospective Study

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Gaayeb, Lobna ^a,b   Sarr, Jean Biram ^b   Ndiath, Mamadou O ^d   Hanon, Jean Baptiste ^a,b   Debrie, Anne Sophie ^a   Seck, Modou ^b   Schacht, Anne Marie ^a,b   Remoué, Franck ^e   Hermann, Emmanuel ^a,b,c   Riveau, Gilles ^a,b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b Biomedical Research Centre EPLS   (Senegal)

^c UNIV LILLE   (France)

^d Laboratoire de Paludologie   (Senegal)

^e CENTRE DE RECHERCHE ENTOMOLOGIQUE DE COTONOU CREC   (Benin)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; BORDETELLA PERTUSSIS; CHILD; COHORT ANALYSIS; ENDEMIC DISEASE; EPIDEMIC; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERTUSSIS; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SENEGAL; SEROPREVALENCE; VACCINATION;

ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; PERTUSSIS TOXIN; POLIOVIRUS VACCINE, INACTIVATED; PROSPECTIVE STUDIES; SENEGAL; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS; VACCINES, COMBINED; WHOOPING COUGH;

BORDETELLA PERTUSSIS;

EID: 84868285086     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048684     Document Type: Article

References (29)

1. World Health Organization (2010) Pertussis vaccines: WHO position paper. Weekly epidemiological record No. 40, 2010, 85, 385-400.
2. Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, et al. (2011) Rationale for pertussis booster vaccination throughout life in Europe. The Lancet infectious diseases 11: 557-570 doi:10.1016/S1473-3099(11)70007-X.
3. Broutin H, Rohani P, Guégan J-F, Grenfell BT, Simondon F, (2004) Loss of immunity to pertussis in a rural community in Senegal. Vaccine 22: 594-596 doi:10.1016/j.vaccine.2003.07.018.
4. Wendelboe AM, Van Rie A, Salmaso S, Englund JA, (2005) Duration of immunity against pertussis after natural infection or vaccination. The Pediatric Infectious Disease Journal 24: S58-61.
5. Guiso N, Liese J, Plotkin SA (2011) The Global Pertussis Initiative: Meeting Report from the Fourth Regional Roundtable Meeting, France, 14-15 April, 2010. Human Vaccines 7.
6. Cherry JD (2010) The Present and Future Control of Pertussis. Clinical Infectious Diseases 51: 663 -667. doi:10.1086/655826.
7. Heikkinen E, Kallonen T, Saarinen L, Sara R, King AJ, et al. (2007) Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PloS one 2: e904 doi:10.1371/journal.pone.0000904.
8. Wood N, McIntyre PB, (2008) Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatric Respiratory Reviews 9: 201-212 doi:10.1016/j.prrv.2008.05.010.
9. Broutin H, Viboud C, Grenfell BT, Miller MA, Rohani P, (2010) Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries. Proceedings of the Royal Society 277: 3239-3245 doi:10.1098/rspb.2010.0994.
10. Simondon F, Préziosi M-P, Yam A, Kane CT, Chabirand L, et al. (1997) A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15: 1606-1612 doi:10.1016/S0264-410X(97)00100-X.
11. Lacombe K, Yam A, Simondon KB, Pinchinat S, Simondon F, (2004) Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine 23: 623-628 doi:10.1016/j.vaccine.2004.07.007.
12. Simondon F, Iteman I, Préziosi M-P, Yam A, Guiso N, (1998) Evaluation of an Immunoglobulin G Enzyme-Linked Immunosorbent Assay for Pertussis Toxin and Filamentous Hemagglutinin in Diagnosis of Pertussis in Senegal. Clinical and Diagnostic Laboratory Immunology 5: 130-134.
13. Préziosi M-P, Yam A, Wassilak SGF, Chabirand L, Simaga A, et al. (2002) Epidemiology of Pertussis in a West African Community before and after Introduction of a Widespread Vaccination Program. American Journal of Epidemiology 155: 891 -896. doi:10.1093/aje/155.10.891.
14. Préziosi M-P, Halloran ME, (2003) Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine 21: 1853-1861 doi:10.1016/S0264-410X(03)00007-0.
15. Findlay JWA, Dillard RF, (2007) Appropriate calibration curve fitting in ligand binding assays. The AAPS Journal 9: E260-267 doi:10.1208/aapsj0902029.
16. de Melker HE, Versteegh FGA, Conyn-Van Spaendonck MA, Elvers LH, Berbers GAM, et al. (2000) Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. Journal of Clinical Microbiology 38: 800-806.
17. Guiso N, Berbers GAM, Fry NK, He Q, Riffelmann M, et al. (2011) What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. European Journal of Clinical Microbiology & Infectious Diseases 30: 307-312 doi:10.1007/s10096-010-1104-y.
18. Riffelmann M, Thiel K, Schmetz J, Wirsing von Koenig CH, (2010) Performance of commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. Journal of clinical microbiology 48: 4459-4463 doi:10.1128/JCM.01371-10.
19. Crowcroft NS, Pebody RG, (2006) Recent developments in pertussis. The Lancet 367: 1926-1936 doi:10.1016/S0140-6736(06)68848-X.
20. Hallander HO, Ljungman M, Storsaeter J, Gustafsson L, (2009) Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 117: 797-807 doi:10.1111/j.1600-0463.2009.02530.x.
21. Gerlach G, von Wintzingerode F, Middendorf B, Gross R, (2001) Evolutionary trends in the genus Bordetella. Microbes and Infection 3: 61-72 doi:10.1016/S1286-4579(00)01353-8.
22. Barenkamp SJ, Leininger E, (1992) Cloning, expression, and DNA sequence analysis of genes encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of Bordetella pertussis. Infection and immunity 60: 1302-1313.
23. Vincent JM, Cherry JD, Nauschuetz WF, Lipton A, Ono CM, et al. (2000) Prolonged afebrile nonproductive cough illnesses in American soldiers in Korea: a serological search for causation. Clinical infectious diseases 30: 534-539 doi:10.1086/313707.
24. Hendrikx LH, Öztürk K, de Rond LGH, Veenhoven RH, Sanders EAM, et al. (2011) Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins. Vaccine 29: 1431-1437 doi:10.1016/j.vaccine.2010.12.033.
25. Broutin H, Mantilla-Beniers NB, Simondon F, Aaby P, Grenfell BT, et al. (2005) Epidemiological impact of vaccination on the dynamics of two childhood diseases in rural Senegal. Microbes and Infection 7: 593-599 doi:10.1016/j.micinf.2004.12.018.
26. Abu Sin M, Zenke R, Rönckendorf R, Littmann M, Jorgensen P, et al. (2009) Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. The Pediatric infectious disease journal 28: 242-244 doi:10.1097/INF.0b013e31818a5d69.
27. Edwards KM, (2005) Overview of Pertussis. The Pediatric Infectious Disease Journal 24: S104-S108 doi:10.1097/01.inf.0000166154.47013.47.
28. Versteegh FGA, Mertens PLJM, de Melker HE, Roord JJ, Schellekens JFP, et al. (2005) Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiology and infection 133: 737-748.
29. Broutin H, Elguero E, Simondon F, Guégan J-F, (2004) Spatial dynamics of pertussis in a small region of Senegal. Proceedings of the Royal Society 271: 2091-2098 doi:10.1098/rspb.2004.2847.